Cargando…

Effects of Simvastatin on Pharmacokinetics and Anticoagulant Effects of Dabigatran in Healthy Subjects

Higher risk of major hemorrhage associated with concomitant use of dabigatran and simvastatin compared to other statins was previously reported with a suggestion of P-glycoprotein-mediated interaction. The aim of this study was to evaluate the effects of simvastatin on pharmacokinetics and anticoagu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chung, Hyewon, Kim, Jong-Min, Park, Jin-Woo, Noh, Jihyeon, Kim, Kyoung-Ah, Park, Ji-Young
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10056008/ https://www.ncbi.nlm.nih.gov/pubmed/36986464 http://dx.doi.org/10.3390/ph16030364

Ejemplares similares

Dabigatran Acylglucuronide, the Major Metabolite of Dabigatran, Shows a Weaker Anticoagulant Effect than Dabigatran
por: Kim, Jong-Min, et al.
Publicado: (2022)

Effect of Cilostazol on the Pharmacokinetics of Simvastatin in Healthy Subjects
por: Kim, Jung-Ryul, et al.
Publicado: (2019)

Pharmacokinetics of a Fixed-Dose Combination Product of Dapagliflozin and Linagliptin and Its Comparison with Co-Administration of Individual Tablets in Healthy Humans
por: Park, Jin-Woo, et al.
Publicado: (2022)

Pharmacokinetics of idarucizumab and its target dabigatran in patients requiring urgent reversal of the anticoagulant effect of dabigatran
por: Glund, Stephan, et al.
Publicado: (2019)

CYP3A5*3 and SLCO1B1 c.521T>C Polymorphisms Influence the Pharmacokinetics of Atorvastatin and 2-Hydroxy Atorvastatin
por: Park, Jin-Woo, et al.
Publicado: (2022)

The Impact of ABCB1 and CES1 Polymorphisms on Dabigatran Pharmacokinetics in Healthy Chinese Subjects
por: Liu, Yue, et al.
Publicado: (2021)

ABCG2 Single Nucleotide Polymorphism Affects Imatinib Pharmacokinetics in Lower Alpha-1-Acid Glycoprotein Levels in Humans
por: Park, Jin-Woo, et al.
Publicado: (2021)

Delayed concentration effect models for dabigatran anticoagulation
por: Eaton, Michael P., et al.
Publicado: (2022)

Pharmacokinetics and Pharmacodynamics of the Nonvitamin K Antagonist Oral Anticoagulant Edoxaban When Administered Alone or After Switching from Rivaroxaban or Dabigatran Etexilate in Healthy Subjects
por: Parasrampuria, Dolly A., et al.
Publicado: (2015)

Pharmacokinetics and Safety of Dabigatran Etexilate after Single and Multiple Oral Doses in Healthy Chinese Subjects
por: Duan, Jingli, et al.
Publicado: (2020)

Pharmacokinetic and pharmacodynamic effects of comedication of clopidogrel and dabigatran etexilate in healthy male volunteers
por: Härtter, Sebastian, et al.
Publicado: (2012)

Comparative pharmacokinetics of Theracurmin, a highly bioavailable curcumin, in healthy adult subjects
por: Chung, Hyewon, et al.
Publicado: (2021)

Promise and challenges of anticoagulation with dabigatran
por: Verma, Ashish, et al.
Publicado: (2012)

Spotlight on idarucizumab and its potential for the reversal of anticoagulant effects of dabigatran
por: Sié, Pierre
Publicado: (2016)

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Cholic Acid (MT921) after a Subcutaneous Injection in the Submental Area to Humans
por: Chung, Hyewon, et al.
Publicado: (2021)

Anticoagulant Related Nephropathy Induced by Dabigatran
por: Sharfuddin, Nazia, et al.
Publicado: (2018)

Use of idarucizumab in reversing dabigatran anticoagulant effect: a critical appraisal
por: Proietti, Marco, et al.
Publicado: (2018)

Effects of uninterrupted dabigatran on the intensity of anticoagulation during atrial fibrillation ablation
por: Osawa, Takumi, et al.
Publicado: (2021)

New options with dabigatran etexilate in anticoagulant therapy
por: Maegdefessel, Lars, et al.
Publicado: (2010)

Features of Pharmacodynamics of the Anticoagulant Dabigatran in Secondary Thrombophilia
por: Kairov, Gaisa T., et al.
Publicado: (2018)

Prothrombin complex concentrates and a specific antidote to dabigatran are effective ex-vivo in reversing the effects of dabigatran in an anticoagulation/liver trauma experimental model
por: Grottke, Oliver, et al.
Publicado: (2014)

Predicted effect of ticagrelor on the pharmacokinetics of dabigatran etexilate using physiologically based pharmacokinetic modeling
por: Wang, Nan, et al.
Publicado: (2020)

Effects of cytochrome P450 oxidoreductase genotypes on the pharmacokinetics of amlodipine in healthy Korean subjects
por: Han, Ji Min, et al.
Publicado: (2020)

Cost-effectiveness analysis of dabigatran and anticoagulation monitoring strategies of vitamin K antagonist
por: Carles, Misericòrdia, et al.
Publicado: (2015)

Effects of direct oral anticoagulants dabigatran and rivaroxaban on the blood coagulation function in rabbits
por: Yin, Lu, et al.
Publicado: (2022)

Influence of FMO3 and CYP3A4 Polymorphisms on the Pharmacokinetics of Teneligliptin in Humans
por: Park, Jin-Woo, et al.
Publicado: (2021)

Pharmacokinetic-pharmacodynamic analysis to evaluate the effect of moxifloxacin on QT interval prolongation in healthy Korean male subjects
por: Hong, Taegon, et al.
Publicado: (2015)

Practical considerations on anticoagulation reversal: spotlight on the reversal of dabigatran
por: Giannandrea, David, et al.
Publicado: (2019)

Monitoring of Anticoagulant Activity of Dabigatran and Rivaroxaban in the Presence of Heparins
por: Jakimczuk, Aleksandra, et al.
Publicado: (2022)

Effect of Upadacitinib on the Pharmacokinetics of Rosuvastatin or Atorvastatin in Healthy Subjects
por: Mohamed, Mohamed‐Eslam F., et al.
Publicado: (2021)

Pharmacokinetic interactions and tolerability of berberine chloride with simvastatin and fenofibrate: an open-label, randomized, parallel study in healthy Chinese subjects
por: Li, Guofei, et al.
Publicado: (2018)

Assessment of the effect of direct oral anticoagulants dabigatran, rivaroxaban, and apixaban in healthy male volunteers using a thrombin generation assay
por: Artang, Ramin, et al.
Publicado: (2017)

Use of Idarucizumab to Revert the Anticoagulant Effect of Dabigatran in Heart Transplant Surgery: An Institutional Experience
por: Herrera-Escandón, Álvaro, et al.
Publicado: (2020)

Effect of Roxadustat on the Pharmacokinetics of Simvastatin, Rosuvastatin, and Atorvastatin in Healthy Subjects: Results From 3 Phase 1, Open‐Label, 1‐Sequence, Crossover Studies
por: Groenendaal‐van de Meent, Dorien, et al.
Publicado: (2022)

Pharmacokinetic and Pharmacodynamic Characteristics of Pelubiprofen Tromethamine vs. Pelubiprofen in Healthy Subjects
por: Son, Yu-Jeong, et al.
Publicado: (2023)

Effects of Ketoconazole on the Pharmacokinetics of Ponatinib in Healthy Subjects
por: Narasimhan, Narayana I, et al.
Publicado: (2013)

Effects of food on the pharmacokinetics of ponatinib in healthy subjects
por: Narasimhan, NI, et al.
Publicado: (2013)

The effect of dolutegravir on the pharmacokinetics of metformin in healthy subjects
por: Zong, Jian, et al.
Publicado: (2014)

The Effect of Dolutegravir on the Pharmacokinetics of Metformin in Healthy Subjects
por: Song, Ivy H., et al.
Publicado: (2016)

The effect of rifampin on the pharmacokinetics of famitinib in healthy subjects
por: Li, Ting, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_vdb2vednmng5k15ejfg2b5e1br